Moderna’s patent dispute with the U.S. government gets at a crucial question: control over how the drug is used

Researchers calculate that the U.S. government provided $2.5 billion toward the development and commercialization of Moderna’s COVID-19 vaccine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.